Search

Displaying results 761 - 770 of 4359 in total
  1. Drug

    Vigabatrin

    go.drugbank.com/drugs/DB01080
    ApprovedInvestigational

    Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. … [A202037] It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent.

  2. Target

    Sodium channel protein type 2 subunit alpha

    go.drugbank.com/bio_entities/BE0002081
    TargetHumans

    Mediates the voltage-dependent sodium ion permeability of excitable membranes. … Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their

    Synonyms: Voltage-gated sodium channel subunit alpha Nav1.2
  3. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma

  4. Drug

    Pyrantel

    go.drugbank.com/drugs/DB11156
    ApprovedVet approved

    In humans, it is administered as pyrantel pamoate [A32282],[A32283],[L1893],[L1898]. … Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base [L1900].

  5. Drug

    Tyloxapol

    go.drugbank.com/drugs/DB06439
    ApprovedInvestigational

    Tyloxapol is a non-ionic detergent often used as a surfactant.

  6. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma … This mechanism results in the targeted release of cytokines such as IL-2, IL-6, and IFN-gamma, promoting the selective lysis of BCMA-expressing cells and offering a novel immunotherapeutic approach for

  7. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). … When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time.

  8. Drug

    Ivacaftor

    go.drugbank.com/drugs/DB08820
    ApprovedInvestigational

    [A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage … CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract.

  9. Drug

    Bicisate

    go.drugbank.com/drugs/DB11164
    Approved

    Bicisate, also known as ethyl cysteinate dimer (ECD), is a N,N'-1,2-ethylene-di-yl-bis-L-cysteinate diethyl ester. … [A32374] The complex of bicisate and technetium Tc99m as a kit was developed by Lantheus Medcl and FDA-approved on November 23, 1994.[L2029]

  10. Drug

    Levonordefrin

    go.drugbank.com/drugs/DB06707
    ApprovedInvestigational

    Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.